

## Literatura ACTA MEDICINAE 10/2025 Revmatologie

- 2 **Postižení nehtů u psoriatické artritidy a možnosti léčby**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Možnosti využití CAR-T terapie v revmatologii**  
prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha; Klinika revmatologie, 1. LF UK, Praha
- 3 **Upadacitinib v léčbě axiálních spondyloartritid**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 3 **Anifrolumab v léčbě systémového lupus erythematoses**  
prof. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 3 **Intersticiální plicní procesy u systémových onemocnění pojiva – screening, monitoring a terapie ve světle aktuálních doporučení**  
prof. MUDr. Michal Tomčík, Ph.D. Revmatologický ústav, Revmatologická klinika, 1. LF UK, Praha
- 4 **Stillova nemoc: nové pohledy na klasifikaci, diagnostiku a terapii**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 4 **Secukinumab – nová léčebná možnost u juvenilní psoriatické artritidy**  
prof. MUDr. Kateřina Bouchalová, Ph.D. Dětská klinika, LF UP a FN Olomouc
- 4 **Využití neopioidních analgetik k léčbě bolesti v revmatologii**  
MUDr. Olga Šléglová Revmatologický ústav a Klinika revmatologie, 1. LF UK, Praha
- 4 **Inaktivita onemocnění a remise u pacientů s juvenilní idiopatickou artritidou léčených tofacitinibem: post hoc analýza fáze III studie**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha
- 5 **Výskyt neinfekční přední uveitidy u dospělých pacientů s imunitně zprostředkovanými zánětlivými onemocněními léčenými tofacitinibem a dalšími pokročilými terapiemi**  
doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

# Postižení nehtů u psoriatické artritidy a možnosti léčby

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Coates, L. C. – Helliwell, P. S.: Psoriatic arthritis: state of the art review. *Clin Med*, 2017, 17, s. 65–70.
- 2 Wilson, F. C. – Icen, M. – Crowson, C. S., et al.: Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Rheum*, 2009, 61, s. 233–239.
- 3 Gisondi, P. – Bellinato, F. – Targher, G., et al.: Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. *Ann Rheum Dis*, 2022, 81, s. 68–73.
- 4 Gossec, L., et al.: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies, 2023 update. *Ann Rheum Dis*, 2024, 0, s. 1–14.
- 5 Pavelka, K. – Mann, H.: Doporučení České reumatologické společnosti pro léčbu psoriatické artritidy. *Česká reumatologie*, 2023, 31, s. 63–74.
- 6 van der Heijde, D. – Cheng-Chung Wei, J. – Dougados, M., et al.: COAST-V study group: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological

- disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet*. 2018 Dec 8;392, s. 2441–2451.
- 7 Deodhar, A. – Poddubnyy, D. – Pacheco-Tena, C., et al.: COAST-W study group: Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomised, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2019, 71, s. 599–611.
  - 8 McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.: Secukinumab, a human anti-interleukin-17A monoclonal antibody in patients with psoriatic arthritis (FUTURE 2) a randomised, double blind, placebo-controlled phase 3 trial. *Lancet*, 2015, 386, s. 1137–1146.
  - 9 Nash, P. – Kirkham, B. – Okada, M., et al.: Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *Lancet*, 2017, 389, s. 2317–2327.

- 10 Smolen, J. S. – Sebba, A. – Ruderman, E., et al.: OP0228 Efficacy and safety of ixekizumab versus adalimumab (SPIRIT-H2H) with and without concomitant conventional synthetic disease-modifying antirheumatic drugs (DMARD) in biologic DMARD-NAIVE patients with psoriatic arthritis: 52 week results. *Ann Rheum Dis*, 2020, 79, suppl. 1, s. 143–144.
- 11 McGonagle, D. – Kavanaugh, A. – McInnes, L., et al.: Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis. Dostupné z: [https://ard.bmj.com/content/82/Suppl\\_1/1124](https://ard.bmj.com/content/82/Suppl_1/1124), vyhledáno 11. 3. 2025.
- 12 Reich, K. – Sullivan, J. – Arenberger, P., et al.: Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. *Br J Dermatol*, 2019, 181, s. 954–966.
- 13 Taylor, W. – Gladman, D. – Helliwell, P., et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum*, 2006, 54, s. 2665–2673.

# Možnosti využití CAR-T terapie v revmatologii

prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha; Klinika revmatologie, 1. LF UK, Praha

- 1 Mohty, M. – Gautier, J. – Malard, F., et al.: CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. *Leukemia*, 2019, 33, s. 2767–2778.
- 2 Kopmar, N. E. – Cassaday, R. D.: Clinical insights on brexucabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia. *Cancer Manag Res*, 2024, 16, s. 1587–1596.
- 3 Khan, S. H. – Choi, Y. – Veena, M., et al.: Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. *Front Immunol*, 2025, 15, 1489827.
- 4 Jin, X. – Han, Y. – Wang, J. Q. – Lu, L., et al.: CAR-T cell therapy: new hope for systemic lupus erythematosus patients. *Cell Mol Immunol*, 2021, 18, s. 2581–2582.
- 5 Pecher, A. C. – Hensen, L. – Lengerke, C., et al.: The Future of CAR T therapeutics to treat autoimmune disorders. *Mol Diagn Ther*, 2024, 28, s. 593–600.
- 6 Schett, G. – Müller, F. – Taubmann, J., et al.: Advancements and challenges in CAR T cell therapy in autoimmune diseases. *Nat Rev Rheumatol*, 2024, 20, s. 531–544.
- 7 Yu, J. – Yang, Y. – Gu, Z., et al.: CAR immunotherapy in autoimmune diseases: promises and challenges. *Front Immunol*, 2024, 15, 1461102.
- 8 Rampotas, A. – Richter, J. – Isenberg, D., et al.: CAR-T cell therapy embarks on autoimmune disease. *Bone Marrow Transplant*, 2025, 60, s. 6–9.
- 9 Ohno, R. – Nakamura, A.: Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies – evidence, safety, and future directions. *Semin Arthritis Rheum*, 2024, 67, 152479.
- 10 Labanieh, L. – Mackall, C. L.: CAR immune cells: design principles, resistance and the next generation. *Nature*, 2023, 614, s. 635–648.
- 11 Scherer, H. U.: Beyond the surface – Autoreactive B cells in human autoimmune diseases. *Semin Arthritis Rheum*, 2024, 64S, 152315.
- 12 Yang, J. – Guo, H. – Han, L., et al.: Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting. *Exp Hematol Oncol*, 2024, 13, s. 25.
- 13 Abeles, I. – Palma, C. – Meednu, N., et al.: B cell-directed therapy in autoimmunity. *Annu Rev Immunol*, 2024, 42, s. 103–126.
- 14 June, Ch. – Sadelain, M.: Chimeric antigen receptor therapy. *N Engl J Med*, 2018, 379, s. 64–73.
- 15 Hernández-López, A. – Téllez-González, M. A. – Mondragón-Terán, P., et al.: Chimeric antigen receptor-T cells: a pharmaceutical scope. *Front Pharmacol*, 2021, 12, 720692.
- 16 Mougiakakos, D. – Sengupta, R. – Gold, R., et al.: Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. *Cytotherapy*, 2025, 27, s. 236–246.
- 17 Siegel, C. H. – Sammaritano, L. R.: Systemic lupus erythematosus: A review. *JAMA*, 2024, 331, s. 1480–1491.
- 18 Aranow, C. – Allaart, C. F. – Amoura, Z., et al.: Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. *Ann Rheum Dis*, 2024, 83, s. 1502–1512.
- 19 Kansal, R. – Richardson, N. – Neeli, I., et al.: Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. *Sci Transl Med*, 2019, 11, eaav1648.
- 20 Mougiakakos, D. – Krönke, G. – Völkl, S., et al.: CD19-targeted CAR T cells in refractory systemic lupus erythematosus. *N Engl J Med*, 2021,

- 385, s. 567–569.
- 21 Mackensen, A. – Müller, F. – Mougiakakos, D., et al.: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med*, 2022, 28, s. 2124–2132.
  - 22 Müller, F. – Taubmann, J. – Bucci, L., et al.: CD19 CAR T-cell therapy in autoimmune disease – a case series with follow-up. *N Engl J Med*, 2024, 390, s. 687–700.
  - 23 He, X. – Hu, B. – Zhang, Y., et al.: Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. *Autoimmun Rev*, 2025, 24, 103692.
  - 24 Krickau, T. – Naumann-Bartsch, N. – Aigner, M., et al.: CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. *Lancet*, 2024, 403, s. 1627–1630.
  - 25 Li, M. – Zhang, Y. – Jiang, N., et al.: Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. *N Engl J Med*, 2024, 391, s. 376–378.
  - 26 Denton, C. P. – Khanna, D.: Systemic sclerosis. *Lancet*, 2017, 390, s. 1685–1699.
  - 27 Lundberg, I. E. – Fujimoto, M. – Vencovsky, J., et al.: Idiopathic inflammatory myopathies. *Nat Rev Dis Primers*, 2021, 7, 86.
  - 28 Bergmann, C. – Müller, F. – Distler, J. H. W., et al.: Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. *Ann Rheum Dis*, 2023, 82, s. 1117–1120.
  - 29 Auth, J. – Müller, F. – Völkl, S., et al.: CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. *Lancet Rheumatol*, 2025, 7, s. e83–e93.
  - 30 Merk, W. – Freitag, M. – Claus, M., et al.: Third-generation CD19. CAR T-cell-containing combination therapy in Scl70+ systemic sclerosis. *Ann Rheum Dis*, 2024, 83, s. 543–546.
  - 31 Claus, M. – Freitag, M. – Ewald, M., et al.: Immunological effects of CD19-CAR-T cell therapy in systemic sclerosis: an extended case study. *Arthritis Res Ther*, 2024, 26, 211.
  - 32 Wang, X. – Wu, X. – Tan, B., et al.: Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. *Cell*, 2024, 187, s. 4890–4904.
  - 33 Muller, F. – Boeltz, S. – Knitzka, J., et al.: CD19-targeted CAR T cells in refractory anti-synthetase syndrome. *Lancet*, 2023, 401, s. 815–818.
  - 34 Pecher, A. C. – Hensen, L. – Klein, R., et al.: CD19-targeting CAR T cells for myositis and interstitial lung disease associated with anti-synthetase syndrome. *JAMA*, 2023, 329, s. 2154–2162.
  - 35 Taubmann, J. – Knitzka, J. – Muller, F., et al.: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. *Rheumatology*, 2024, 63, s. e12–e14.
  - 36 Qin, C. – Dong, M. H. – Zhou, L. Q., et al.: Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. *Proc Natl Acad Sci U S A*, 2024, 121, e2315990121.
  - 37 Haghikia, A. – Hegelmaier, T. – Wolleschak, D., et al.: Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. *Ann Rheum Dis*, 2024, 83, s. 1597–1598.
  - 38 Szabo, D. – Balogh, A. – Gopcsa, L., et al.: Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. *RMD Open*, 2024, 10, e004727.
  - 39 Albach, F. N. – Minopoulou, I. – Wilhelm, A., et al.: Targeting autoimmunity with CD19-CAR T cell therapy: efficacy and seroconversion

- in diffuse systemic sclerosis and rheumatoid arthritis. *Rheumatology*, 2025, keaf077.
- 40 Lidar, M. – Rimar, D. – David, P., et al.: CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. *Ann Rheum Dis*, 2025, 84, s. 370–372.
  - 41 Scherer, H. U. – Huizinga, T. W. J. – Krönke, G., et al.: The B cell response to citrullinated antigens in the development of rheumatoid arthritis. *Nat Rev Rheumatol*, 2018, 14, s. 157–169.
  - 42 Kattamuri, L. – Mohan, L. B. – Vojjala, N., et al.: Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. *Rheumatol Int*, 2025, 45, 18.
  - 43 Minopoulou, I. – Wilhelm, A. – Albach, F., et al.: Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. *Ann Rheum Dis*, 2025, 84, s. e4–e7.
  - 44 Levine, B. L. – Pasquini, M. C. – Connolly, J. E., et al.: Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. *Nat Med*, 2024, 30, s. 338–341.
  - 45 Jain, M. D. – Smith, M. – Shah, N. N.: How I treat refractory CRS and ICANS after CAR-T cell therapy. *Blood*, 2023, 141, s. 2430–2442.
  - 46 Bupha-Intr, O. – Haeusler, G. – Chee, L., et al.: CAR-T cell therapy and infection: a review. *Expert Rev Anti Infect Ther*, 2021, 19, s. 749–758.
  - 47 Hagen, M. – Müller, F. – Wirsching, A., et al.: Local immune effector cell-associated toxicity syndrome in CAR-T-cell treated patients with autoimmune disease: an observational study. *Lancet Rheumatol*, 2025, doi: 10.1016/S2665-9913(25)00091-8.
  - 48 Diorio, C. – Teachey, D. T. – Grupp, S. A.: Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. *Nat Rev Clin Oncol*, 2025, 22, s. 10–27.
  - 49 Feng, X. – Li, Z. – Liu, Y., et al.: CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. *Exp Hematol Oncol*, 2024, 13, 102.
  - 50 Gheithi, M. – Safdel, S. – Kumar Patra, S., et al.: Generation of immune cells from induced pluripotent stem cells (iPSCs): Their potential for adoptive cell therapy. *Hum Immunol*, 2024, 85, 110836.
  - 51 Bulliard, Y. – Freeborn, R. – Uyeda, M. J., et al.: From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. *Front Immunol*, 2024, 15, 1509956.
  - 52 Mougiakakos, D. – Meyer, E. – Schett, G.: CAR-T-cells in autoimmunity: game changer or stepping stone? *Blood*, 2025, 145, s. 1841–1849.
  - 53 Tur, C. – Eckstein, M. – Velden, J., et al.: CD19-CAR T-cell therapy induces deep tissue depletion of B cells. *Ann Rheum Dis*, 2025, 84, s. 106–114.
  - 54 Cheever, A. – Kang, C. C. – O'Neill, K. L., et al.: Application of novel CAR technologies to improve treatment of autoimmune disease. *Front Immunol*, 2024, 15, 1465191.
  - 55 Furie, R. A. – Rovin, B. H. – Garg, J. P., et al.: REGENCY trial investigators: Efficacy and safety of obinutuzumab in active lupus nephritis. *N Engl J Med*, 2025, 392, s. 1471–1483.
  - 56 Bucci, L. – Hagen, M. – Rothe, T., et al.: Bispecific T cell engager therapy for refractory rheumatoid arthritis. *Nat Med*, 2024, 30, s. 1593–1601.
  - 57 Alexander, T. – Krönke, J. – Cheng, Q., et al.: Teclistamab-induced remission in refractory systemic lupus erythematosus. *N Engl J Med*, 2024, 391, s. 864–866.
  - 58 Schett, G. – Nagy, G. – Krönke, G., et al.: B-cell depletion in autoimmune diseases. *Ann Rheum Dis*, 2024, 83, s. 1409–1420.

# Upadacitinib v léčbě axiálních spondyloartritid

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Sieper, J., et al.: Axial spondyloarthritis. *Lancet*, 2017, 390, s. 73–84.
- 2 Rudwaleit, M., et al.: The development of assessment of ASAS classification criteria for axial spondyloarthritis. Part II – validation and final selection. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- 3 Frison, E., et al.: How to translate genetic findings into clinical applications in spondyloarthritis? *Front Immunol*, 2024, 15, doi.org/10.3389/fimmu.2024.1301735
- 4 Ferran, Y., et al.: Environmental risks for spondyloarthritis. *Rheum Dis Clin North Am*, 2022, 48, s. 813–826.
- 5 Wendling, D., et al.: Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis task force workshop. *Join Bone Spine*, 2024, 91, 105741.
- 6 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu axiálních spondyloartritid. *Česká Revmatol*, 2021, 29, s. 5–19.
- 7 Hušáková, M., et al.: Doporučení České revmatologické společnosti pro farmakologickou léčbu axiálních spondyloartritid. *Čes Revmatol*, 2021, 29, s. 65–77.
- 8 Ramiro, S., et al.: ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*, 2023, 82, s. 19–34.
- 9 van der Heijde, D., et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomised, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
- 10 Braun, J., Baraliakos, X., Deodhar, A., et al.: Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. *Ann Rheum Dis*, 2017, 76, s. 1070–1077.
- 11 van der Heijde, D., Cheng-Chung Wei, J., Dougados, M., et al.: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet*, 2018, 392, s. 2441–2451.
- 12 van der Heijde, D., Deodhar, A., Baraliakos, X., et al.: Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. *Ann Rheum Dis*, 2023, 82, s. 515–526.
- 13 van der Heijde, D., et al.: Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. *Lancet*, 2019, 394, s. 2108–2117.
- 14 Deodhar, A., et al.: Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. *Arthritis Rheumatol*, 2022, 74, s. 70–80.
- 15 van der Heijde, D., et al.: Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. *RMD Open*, 2022, 8, e002280.
- 16 van der Heijde, D., et al.: Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. *Ann Rheum Dis*, 2022, 81, s. 1515–1523.
- 17 Baraliakos, X., et al.: Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. *Arthritis Res Ther*, 2023, 25, s. 172.
- 18 Baraliakos, X.: Efficacy and safety of upadacitinib in patients with active AS refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS study. *Arthritis Res Ther*, 2024, 26, s. 197.
- 19 Tang, H. M., et al.: Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety. *Clin Rheumatol*, 2024, 43, s. 2391–2401.
- 20 Baraliakos, X., et al.: Comparative efficacy of advanced therapies in the treatment of radiographic axial spondyloarthritis or ankylosing spondylitis as evaluated by the ASDAS low disease activity criteria. *Rheumatol Ther*, 2024, 11, s. 989–999.
- 21 Walsh, J. A., et al.: Clinical and economic benefit of advanced therapies for the treatment of active ankylosing spondylitis. *Rheumatol Ther*, 2023, 10, s. 1385–1398.
- 22 Bechman, K., et al.: A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. *Rheumatology*, 2019, 58, s. 1755–1766.
- 23 Ytterberg, S. R., et al.: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med*, 2022, 386, s. 316–326.
- 24 Khostrow-Khavar, F., et al.: Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. *Ann Rheum Dis*, 2022, 81, s. 798–804.
- 25 Aymen, R., et al.: OP 1 Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDs: data from an international collaboration of registries (the “JAK-pot” study). Dostupné z: <https://research.manchester.ac.uk/en/publications/op-1-incidence-of-major-adverse-cardiovascular-events-in-patients>, vyhledáno 8. 4. 2025.
- 26 ASAS Definition of Difficult-to-Manage Axial Spondyloarthritis – ASAS D2T SpAM. Dostupné z: <https://www.asas-group.org/asas-definition-of-difficult-to-treat-axial-spondyloarthritis/>, vyhledáno 8. 4. 2025.
- 27 Van der Cruyssen, B., et al.: The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. *Ann Rheum Dis*, 2007, 66, s. 1072–1077.
- 28 Fakhri, D., et al.: Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study. *Open*, 2023, 9, e003461.
- 29 Ono, K., Kishimoto, M.: Is JAK inhibitor the option to prevent difficult-to-manage axial spondyloarthritis? *Int J Rheum Dis*, 2024, 27, e15329.
- 30 Proft, F., Duran, T. I., Ghoreschi, K., et al.: Treatment strategies for spondyloarthritis: implementation of precision medicine – or “one size fits all” concept? *Autoimmunity Reviews*, 2024, 23, 103638.
- 31 RINVOQ SPC, datum revize textu: 04/2025.

# Anifrolumab v léčbě systémového lupus erythematosus

prof. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 Onuora, S.: Positive results for anifrolumab in phase III SLE trial. *Nat Rev Rheumatol*, 2020, 16, 125.
- 2 Wahadat, M. J., et al.: Type I IFN signature in childhood-onset SLE: a conspiracy of DNA- and RNA-sensing receptors? *Arthritis Res Ther*, 2018, 20, 4, doi: 10.1186/s13075-017-1501-z
- 3 Furie, R. A., et al.: Anifrolumab, an anti-interferon- $\alpha$  receptor monoclonal antibody, in moderate to severe SLE. *Arthritis Rheumatol*, 2017, 69, s. 376–386.
- 4 Furie, R. A., et al.: Type I interferon inhibitor anifrolumab in active SLE (TULIP-1): a randomized, controlled, phase 3 trial. *Lancet Rheumatol*, 2019, 1, s. E208–E219.
- 5 Morand, E. F., et al.: Trial of anifrolumab in active systemic lupus erythematosus (TULIP-2). *N Engl J Med*, 2020, 382, s. 211–221, doi: 10.1056/NEJMoa1912196.
- 6 Furie, R., et al.: Long-term safety and efficacy of anifrolumab in adults with SLE: Phase II open-label extension study. *Arthritis Rheumatol*, 2021, 73, s. 816–825.
- 7 Miyazaki, Y., et al.: Safety and efficacy of anifrolumab in SLE in real-world clinical practice: LOOPS registry. *Rheumatology*, 2024, 63, s. 2345–2354.
- 8 Cardelli, C., et al.: Anifrolumab in refractory systemic lupus erythematosus: a real-life multicenter study. *J Rheumatol*, 2024, 51, s. 1096–1101.
- 9 Fanouriakis, A., et al.: 2023 update of the EULAR recommendations for the management of SLE. *Ann Rheum Dis*, 2024, 83, s. 15–29.
- 10 Morand, E. F., et al.: LDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. *Ann Rheum Dis*, 2025, 84, s. 777–788.
- 11 Touma, Z., et al.: Reduced organ damage accumulation in SLE with anifrolumab plus standard care vs. real-world controls. *Ann Rheum Dis*, 2025, 84, s. 767–776.

# Intersticiální plicní procesy u systémových onemocnění pojiva – screening, monitoring a terapie ve světle aktuálních doporučení

prof. MUDr. Michal Tomčík, Ph.D. Revmatologický ústav, Revmatologická klinika, 1. LF UK, Praha

- 1 Wijsenbeek, M., Cottin, V.: Spectrum of fibrotic lung diseases. *N Engl J Med*, 2020, 383, s. 958–968.
- 2 Joy, G. M., Arbiv, O. A., Wong, C. K., et al.: Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. *Eur Respir Rev*, 2023, 32, 220210.
- 3 Olson, A., Hartmann, N., Patnaik, P., et al.: Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. *Adv Ther*, 2021, 38, s. 854–867.
- 4 Gibson, C. D., Kugler, M. C., Deshwal, H., et al.: Advances in targeted therapy for progressive fibrosing interstitial lung disease. *Lung*, 2020, 198, s. 597–608.
- 5 Elhai, M., Meune, C., Boubaya, M., et al.: Mapping and predicting mortality from systemic sclerosis. *Ann Rheum Dis*, 2017, 76, s. 1897–1905.
- 6 Johnson, S. R., Bernstein, E. J., Bolster, M. B., et al.: 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. *Arthritis Rheumatol*, 2024, 76, s. 1182–1200.
- 7 Sehgal, S., Patel, A., Chatterjee, S., et al.: Idiopathic inflammatory myopathies related lung disease in adults. *Lancet Respir Med*, 2025, 13, s. 272–288.
- 8 George, P. M., Spagnolo, P., Kreuter, M., et al.: Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respir Med*, 2020, 8, s. 925–934.
- 9 Raghu, G., Remy-Jardin, M., Richeldi, L., et al.: Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med*, 2022, 205, s. e18–e47.
- 10 Flaherty, K. R., Wells, A. U., Cottin, V., et al.: Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med*, 2019, 381, s. 1718–1727.
- 11 Johnson, S. R., Bernstein, E. J., Bolster, M. B., et al.: 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. *Arthritis Rheumatol*, 2024, 76, s. 1182–1200.
- 12 Saavedra, A. A., Mueller, K. T., Kowalski, E. N., et al.: Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline. *Curr Treatm Opt Rheumatol*, 2024, 10, s. 43–60.
- 13 Molina-Molina, M., Castellví, I., Valenzuela, C., et al.: Management of progressive pulmonary fibrosis associated with connective tissue disease. *Expert Rev Respir Med*, 2022, 16, s. 765–774.
- 14 Furini, F., Carnevale, A., Casoni, G. L., et al.: The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. *Front Med*, 2019, 6, 246.
- 15 Alunno, A., Gerli, R., Giacomelli, R., Carubbi, F.: Clinical, epidemiological, and histopathological features of respiratory involvement in rheumatoid arthritis. *Biomed Res Int*, 2017, 2017, 7915340.
- 16 Lopez Velazquez, M., Highland, K. B.: Pulmonary manifestations of systemic lupus erythematosus and Sjögren's syndrome. *Curr Opin Rheumatol*, 2018, 30, s. 449–464.
- 17 Perelas, A., Arrossi, A. V., Highland, K. B.: Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. *Clin Chest Med*, 2019, 40, s. 501–518.

# Stillova nemoc: nové pohledy na klasifikaci, diagnostiku a terapii

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Still, G. F., et al.: On a form of chronic joint disease in children. *Med Chir Trans*, 1897, 80, s. 47–60.
- 2 Bywaters, E. G., et al.: Still disease in adult. *Ann Rheum Dis*, 1971, 30, s. 121–133.
- 3 Ansell, B.: Heberden Oration, 1977. Chronic arthritis in childhood. *Ann Rheum Dis*, 1978, 37, s. 107–120.
- 4 Fautrel, B.: EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. *Ann Rheum Dis*, 2024, 83, s. 1614–1627.
- 5 Alonso, E. R., et al.: Adult onset Still's disease: review of 26 cases. *Med Clin*, 2007, 129, s. 258–261.
- 6 De Mateis, M., et al.: Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease. *Ann Rheum Dis*, 2024, 83, s. 1748–1761.
- 7 Georgin-Lavaile, S., et al.: Systemic autoinflammatory diseases: Clinical state of the art. *Best Pract Res Clin Rheumatol*, 2020, 34, 101529.
- 8 Bondoli, S., et al.: Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease. *Ann Rheum Dis*, 2024, 83, 1731–1747.
- 9 Nigrovic, P.: Macrophage activation syndrome. *Arthritis Rheum*, 2025, 77, s. 367–379.
- 10 Benedetti, D., et al.: Efficacy and safety of emapalumab in MAS. *Ann Rheum Dis*, 2023, 2, s. e857–e865.
- 11 Mehta, P.: Silencing the cytokine storm: the use of intravenous anakinra in MAS. *Lancet Rheumatol*, 2020, 2, s. e358–e367.
- 12 Keenan, C.: Use of JAK inhibitor ruxolitinib in the treatment haemophagocytic lymphohistiocytosis. *Front Immunol*, 2021, 12, 614704.
- 13 Bracaglia, C., et al.: POSO277 systemic JIA associated lung disease in Europe. *Ann Rheum Dis*, 2023, 82, 1–379.
- 14 Klic, B.: Anakinra in the management of adult-onset Still's disease: a single-center experience. *Intern Emerg Med*, 2025, 20, s. 131–138.
- 15 Kedor, C., et al.: Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. *Ann Rheum Dis*, 2020, 79, s. 1090–1097.
- 16 Kaneko, Y., et al.: Tocilizumab in patients with adult onset stills disease refractory to glucocorticoid treatment. *Ann Rheum Dis*, 2018, 77:172–179.
- 17 Hu, Q., Yang, Ch.: EULAR and PReS bridge the age gap in Still's disease. *Nat Rev Rheumatol*, 2025, 21, 5–6.
- 18 Liao, J., et al.: The efficacy and safety of JAK inhibitors in patients with adult-onset Still's disease: A meta-analysis and systematic review. *Int Immunopharmacol*, 2024, 137, 112451.
- 19 Onel, K. B., et al.: 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Care Res*, 2022, 74, s. 521–537.

# Secukinumab – nová léčebná možnost u juvenilní psoriatické artritidy

prof. MUDr. Kateřina Bouchalová, Ph.D. Dětská klinika, LF UP a FN Olomouc

- 1 Petty, R. E. – Laxer, R. M. – Wedderburn, L. R.: Juvenile idiopathic arthritis. In: Petty, R. E. – Laxer, R. M. – Lindsley, C. B. – Wedderburn, L. R.: *Textbook of Pediatric Rheumatology*. Elsevier, Philadelphia, 2021, s. 209–293.
- 2 Sandborg, C. I. – Schulert, G. S. – Kimura, Y.: Juvenile idiopathic arthritis. *N Engl J Med*, 2025, 393, s. 162–174, doi: 10.1056/NEJMra2402073.
- 3 Srinivasalu, H. – Sikora, K. A. – Colbert, R. A.: Recent updates in juvenile spondyloarthritis. *Rheum Dis Clin North Am*, 2021, 47, s. 565–583.
- 4 Hinks, A. – Bowes, J. – Cobb, J., et al.: Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. *Ann Rheum Dis*, 2017, 76, s. 765–772.
- 5 Hinks, A. – Martin, P. – Flynn, E., et al.: Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. *Arthritis Res Ther*, 2011, 13, R12.
- 6 Balay-Dustrude, E. – Weiss, N. S. – Sutton, A. – Shenoi, S.: Predictors of disease activity in patients with juvenile idiopathic arthritis at 12 and 24 months after diagnosis. *ACR Open Rheumatol*, 2024, 6, s. 489–496, doi: 10.1002/acr2.11701.
- 7 Rebollo-Giménez, A. I. – Rosina, S. – Natoli, V., et al.: Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study. *Clin Exp Rheumatol*, 2024, 42, s. 757–763, doi: 10.55563/clinexprheumatol/7xby7y.
- 8 Bouchalová, K. – Čelková, M.: Juvenilní idiopatická artritida. In: Zadrazil, J. – Horák, P. – Karásek, D.: *Moderní farmakoterapie autoimunitních chorob*. Maxdorf, Praha, 2024.
- 9 Brunner, H. I. – Foeldvari, I. – Alexeeva, E., et al.: Efficacy and safety of secukinumab in juvenile psoriatic arthritis and enthesitis-related arthritis: results from a randomized, double-blind, placebo-controlled phase 3 study. *Ann Rheum Dis*, 2023, 82, s. 154–160.
- 10 Leu, J. H. – Shiff, N. J. – Clark, M., et al.: Intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis and subcutaneous ustekinumab in patients with juvenile psoriatic arthritis: extrapolation of data from studies in adults and adjacent pediatric populations. *Paediatr Drugs*, 2022, 24, s. 699–714.
- 11 Shenoi, S. – Horneff, G. – Aggarwal, A. – Ravelli, A.: Treatment of non-systemic juvenile idiopathic arthritis. *Nat Rev Rheumatol*, 2024, 20, s. 170–181.
- 12 Ramanan, A. V. – Dick, A. D. – Jaki, T., et al.: Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. *Pediatr Rheumatol Online J*, 2025, 23, s. 55, doi: 10.1186/s12969-025-01107-1.
- 13 Bouchalová, K.: První zkušenosti se secukinumabem u psoriatické juvenilní idiopatické artritidy. *Farmakoterapeutická revue*, 2025, č. 5.
- 14 European Medicines Agency (EMA). Souhrn údajů o přípravku Cosentyx [online]. Dostupné z: [https://www.ema.europa.eu/cs/documents/overview/cosentyx-epar-medicine-overview\\_cs.pdf](https://www.ema.europa.eu/cs/documents/overview/cosentyx-epar-medicine-overview_cs.pdf), vyhledáno 4. 9. 2025.

# Využití neopioidních analgetik k léčbě bolesti v revmatologii

MUDr. Olga Šlégllová Revmatologický ústav a Klinika revmatologie, 1. LF UK, Praha

- 1 Goldberg, D. S. – McGee, S. J.: Pain as a global public health priority. *BMC Public Health*, 2011, 11, s. 770.
- 2 Pavelka, K. – Vencovský, J. – Šenolt, L., et al.: *Farmakoterapie revmatických onemocnění*. Maxdorf, Praha, 2017.
- 3 Rokyta, R. – Kršiak, M. – Kozák, J., et al.: *Bolest*. Tjgis, Praha, 2006.
- 4 Doležal, T. – Hakl, M. – Kozák, J., et al.: Metodické pokyny pro farmakoterapii akutní a chronické nenádorové bolesti. *Vnitř Lék*, 2007, 53, s. 79–90.
- 5 Kozák, J. – Lejško, J. – Fricová, J., et al.: Metodické pokyny pro farmakoterapii chronické bolesti. *Bolest*, 2022, 25, s. S17–S42.
- 6 Slíva, J. – Doležal, T.: *Farmakoterapie bolesti*. Maxdorf, Praha, 2009.
- 7 Schug, S. A. – Garrett, W. R. – Gillespie, G.: Opioid and non-opioid analgesics. *Best Pract Res Clin Anaesthesiol*, 2003, 17, s. 91–110.
- 8 Gaertner, J. – Stamer, U. M. – Remi, C., et al.: Metamizole/dipyrone for the relief of cancer pain: a systematic review and evidence-based recommendations for clinical practice. *Palliat Med*, 2017, 31, s. 26–34.
- 9 Jasiacka, A. – Maślanka, T. – Jaroszewski, J. J.: Pharmacological characteristics of metamizole. *Pol J Ver Sci*, 2014, 17, s. 207–214.
- 10 Šimíček, M.: Oxfordská liga analgetik a terapie akutní bolesti z pohledu farmaceuta. *Praktické lékárenství*, 2015, 5, s. 54–58.
- 11 Castellsague, J. – Riera-Guardia, N. – Calingaert, B., et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). *Drug Saf*, 2012, 35, s. 1127–1146.
- 12 Patel, P. B. – Patel, T. K.: Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. *Eur J Rheumatol*, 2017, 4, s. 11–18.
- 13 Bannuru, R. R. – Osani, M. C. – Vaysbrot, E. E., et al.: OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage*, 2019, 27, s. 1578–1589.
- 14 Iolascon, G. – Giménez, S. – Mogyorósi, D.: A review of aceclofenac: analgesic and anti-inflammatory effects on musculoskeletal disorders. *J Pain Res*, 2021, 14, s. 3651–3663.
- 15 Emery, P. – Zeidler, H. – Kvien, T. K., et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. *Lancet*, 1999, 354, s. 2106–2111.
- 16 Kivitz, A. J. – Moskowitz, R. W. – Woods, E., et al.: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. *J Int Med Res*, 2001, 29, s. 467–479.
- 17 Geba, B. P. – Weaver, A. L. – Polis, A. B., et al.: Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomised trial. *JAMA*, 2002, 287, s. 64–71.
- 18 Derry, S. – Moore, R. A. – Gaskell, H., et al.: Topical NSAIDs for acute musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 2015, CD007402.
- 19 Derry, S. – Wiffen, P. J. – Kalso, E. A., et al.: Topical analgesics for acute and chronic pain in adults – an overview of Cochrane Reviews. *Cochrane Database Syst Rev*, 2017, 5, CD008609.
- 20 Dostupné z: [https://prehledy.sukl.cz/prehled\\_leciv.html#/](https://prehledy.sukl.cz/prehled_leciv.html#/), vyhledáno 3. 3. 2025.

# Inaktivita onemocnění a remise u pacientů s juvenilní idiopatickou artritidou léčených tofacitinibem: post hoc analýza fáze III studie

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

- 1 Consolaro, A. – Ruperto, N. – Lovell, D. J., et al.: Clinically inactive disease and remission in patients with juvenile idiopathic arthritis receiving tofacitinib: post hoc analysis of a phase III trial. *J Rheum*, 2025, doi:10.3899/jrheum.2024-0536.

# Výskyt neinfekční přední uveitidy u dospělých pacientů s imunitně zprostředkovanými zánětlivými onemocněními léčenými tofacitinibem a dalšími pokročilými terapiemi

doc. MUDr. Jiří Slíva, Ph.D., MBA Ústav farmakologie, 3. LF UK, Praha

1 **Ogdie, A., et al.**: OP0375 Incidence of non-infectious anterior uveitis among adult patients with immune-mediated inflammatory diseases treated with tofacitinib and other advanced therapies. *Ann Rheum Dis*, 2025, 84, s. 302–303.